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Abstract
Enterovirus 71 (EV71)-associated hand, foot and mouth disease has emerged as a serious public health problem in South
East Asia over the last decade. To better understand the prevalence of EV71 infection, we determined EV71 seroprevalence
and seroincidence amongst healthy infants and children in Ho Chi Minh City, Viet Nam. In a cohort of 200 newborns, 55% of
cord blood samples contained EV71 neutralizing antibodies and these decayed to undetectable levels by 6 months of age in
98% of infants. The EV71 neutralizing antibody seroconversion rate was 5.6% in the first year and 14% in the second year of
life. In children 5–15 yrs of age, seroprevalence of EV71 neutralizing antibodies was 84% and in cord blood it was 55%.
Taken together, these data suggest EV71 force of infection is high and highlights the need for more research into its
epidemiology and pathogenesis in high disease burden countries.
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Introduction
Hand, foot and mouth disease (HFMD) is a common, highly
infectious childhood viral disease that can be transmitted from
person to personthrough the fecal-oralor respiratory route. Typical
clinical manifestations include a brief fever followed by pharyngitis,
mouth ulcers and vesicular rash on the palms of the hands and the
soles of the feet. Children may have reduced appetite due to painful
vesicles in the mouth cavity. Children less than 5 years of age
account for the majority of hospitalized HFMD cases [1,2,3,4] and
although it is usually mild and self-limiting, severe organ
impairment can occur which occasionally leads to death [4,5].
Large epidemics of HFMD in the World Health Organization’s
Western Pacific Region have recently been described [5] and have
been associated with severe and fatal outcomes [6,7,8].
HFMD is caused by members of the Enterovirus genus, mainly,
coxsackievirus A16 or enterovirus 71 [9]. In addition, sporadic
cases with coxsackievirus types A4–A7, A9, A10, B1–B3, and B5
have been reported [2,9]. Human enterovirus 71 (EV71) has been
more frequently associated with severe forms of HFMD such as
aseptic meningitis, polio-like paralysis and/or encephalitis [5]. The
basis for the relatively greater virulence of EV71 is unclear but
might be associated with viral genetics [10]. There are no vaccines
or specific therapies to prevent or treat severe HFMD.
HFMD has emerging as a public health problem in the south of
Viet Nam and is associated primarily with Coxsackievirus A16 or
EV71 infection. A previous study by Tu et al. outlined the age-
related epidemiology of hospitalized EV71-associated HFMD in
the largest children’s hospital in Ho Chi Minh City [2]. To more
fully explore the scale of EV71 virus transmission in the healthy
infants and children in Ho Chi Minh City, we undertook a
prospective seroincidence survey of a cohort of newborn infants
followed from birth to their 2
nd birthday. In parallel, we conducted
a cross-sectional sero-prevalence study of EV71 neutralizing
antibodies in Vietnamese children and adults.
Materials and Methods
The study protocol were approved by the Scientific and Ethical
committees at Hung Vuong Obstetric Hospital, Hospital for
Tropical Diseases and the Oxford University Tropical Research
Ethical committee. Written informed consent was obtained from
the mother in the birth cohort study and the accompanying
parent/guardian in the community dengue study.
Collection of cord and infant plasma samples
The decay of maternally derived anti-EV71 neutralizing
antibodies and the seroincidence of EV71 infection in the first year
of life was determined using serial plasma samples collected from
200 infants born at Hung Vuong Obstetric Hospital, Ho Chi Minh
City, between September 2006–September 2007. All 200 infants
were participants in a prospective birth cohort, the methods for
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blood was collected at the time of birth and plasma samples were
collected at four follow-up visits (3, 6, 9 and 12 months).
Collection of plasma samples in a cross-sectional survey
of children and young adults
To determine the age-related seroprevalence of EV71 neutral-
izing antibodies in relatively older children we collected plasma
from 263 young children at 12-, 18- and 24- months of age, and 120
children aged from 5–15 years. The plasma samples from infants
aged 12 or 24 months of age were collected in the same birth cohort
study described previously but who were not represented in the 200
infants in whom seroincidence rates were determined. The plasma
samples from children aged 5–15 years were collected as part of a
community-based study of dengue at District 8 Hospital, Ho Chi
Minh City between September 2005–January 2009. Participants
were children with suspected dengue. For the purposes of
determining EV71 seroprevalence levels in this age group, we
selected plasma samples from 120 children between 5 and 15 yrs of
age from whom blood samples had been collected $14 days after
study enrolment and who had no serological or virological evidence
of dengue infection. The diagnosis in these ‘‘not dengue’’ cases was
not determined, but were presumed viral infections. There was no
clinical evidence to suggest these were HFMD cases. Cord blood
were used to provide the results in young adults.
EV71 virus neutralization assay
We defined neutralizing antibody levels in plasma to an EV71
virus (EV71/7423/MS87) isolated in Mississippi USA in 1987. In
brief, the experiments were run in 96-well plates. Vero cells were
prepared at 10
4 cells/well and left overnight. Diluted plasma was
incubated with EV71/7423/MS87 for 1.5 hours, and then
incubated with plated Vero cells at 37uC, 5% CO2 for 5 days.
The final multiplicity of infection (MOI) was 0.01. Each plasma
dilution was tested in duplicate. Results were documented visually
by reading the cytopathic effect (CPE) through an inverted
microscope at day 5. The plasma neutralization titre was defined
as the reciprocal of the dilution of plasma required to neutralize
$50% of the virus-infected wells. An antibody titre of 20 was the
limit of detection using this method.
Statistical analysis
Statistical analyses were performed with SPSS version 14. P,.05
was considered to indicate statistical significance. We used the
Mann Whitney U test to compare titre values between age groups.
The EV71 infection incidence was calculated by observing the
EV71 neutralizing-antibody (Neut-Ab) seroconversion rates among
463 infants during the first 2 years of life. We stopped counting the
time that an infant contributed to the study whenever the infant
showed evidence of EV71 neutralizing-antibody seroconversion, at
thetime ofwithdrawalfromthestudy,orattheconclusionoffollow-
up.TheincidenceofEV71infectionwasexpressedasthenumberof
EV71 Neut-Ab seroconversions per 100 person-years.
Results
Seroprevalence of virus neutralizing antibodies to EV71
in cord plasma and the decay of maternally-derived
antibodies in infants
Amongst 200 cord plasma samples collected during 2006–2007
from infants born in Ho Chi Minh City, 110 (55%) had detectable
levels of virus neutralizing antibodies to EV71. To estimate the
rate of decay of maternally-derived EV71 neutralizing antibodies,
we measured their levels in serial plasma samples from infants in
whom the cord blood EV71 neutralizing antibody titre was $80.
The rationale for this was that preliminary data indicated that
cord blood samples with titres #40, were below the limit of
detection by the time the infant was 3 months of age. In the 34
infants in whom the EV71 neutralizing antibody titre was $80 in
cord plasma, the geometric mean titre (GMT) was 220 (95% CI:
133–307). At 3 months of age, 12 (50%) of these infants still had
detectable EV71 neutralizing antibody (GMT 48 (95% CI: 38–58))
whilst at 6 months of age only 2 (6%) had detectable neutralizing
antibody (GMT 28 (95% CI: 9–47) (Fig. 1). Maternally-derived
EV71 neutralizing antibody could not be detected in any of the
infants at 9- or 12-months of age.
Seroincidence of EV71 infection in the first two years of
life
We used 1253 plasma samples collected between birth and two
years of age from the 200 infants in whom the decay of maternal
antibody was previously described and 383 plasma samples
collected between 12- to 24-months of age from 263 independent
young children to determine the seroincidence of EV71 infection.
In the cohort of 200 infants, participants provided plasma samples
every 3 months from birth to one year of age, with 42 providing a
further sample at 18 months of age only, 94 providing samples at
18 and 24 months of age and 23 providing samples at 24 months
of age only. The 263 independent young children provided 116,
260 and 259 plasma samples at 12, 18 and 24 month respectively.
This sampling provided 6156 months of surveillance in total.
EV71 infection was defined by the acquisition of virus neutralizing
antibodies (seroconversion) or four-fold rise in EV71 neutralizing
antibody titer. In the first year of life, 17/304 (6%) infants had
evidence of EV71 infection, equivalent to an incidence rate of 5.6
per 100 person-years. The majority of these infections (12/17,
70%) occurred in months of the year previously associated with
HFMD epidemics in Ho Chi Minh City (HCMC), from August to
December [2]. In the 2
nd year of life, 37/303 (12%) infants had
evidence of EV71 infection, equivalent to a rate of 14 infections
per 100 person-years (Table 1). Cumulatively, by two years of age,
54/463 (11.7%) of infants in this cohort had serological evidence
of EV71 infection. EV71 Neut-Ab profiles prior to and subsequent
Figure 1. Decline of maternally-derived Neut-Ab to EV71 in 37
infants in the first year of life. The scatter plot shows Neut-Ab titres
in 37 individual infants from the time of birth to 12 months. These
infants all had Neut-Ab titre to Ev71 $80 at birth. The infant having a
detectable titre at 6 months had the highest Ab titre at birth (1280).
Maternal Neut-Ab to EV71 were not detected in these infants at 9 and
12 months of age. The dashed line represents the limit of detection of
the assay.
doi:10.1371/journal.pone.0021116.g001
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(Fig. 2A) and four young children infected in the second year of life
are illustrated in Fig. 2B.
Collectively, these data suggest EV71 infection was common in
this cohort of Vietnamese infants. Insight into the severity of these
EV71 infections was inferred from interviews with the parents/
guardians of each infant at each follow-up visit. Surprisingly, none
of these infants with serologically-defined EV71 infections ever
received a clinical diagnosis of HFMD at a hospital or health care
provider, suggesting clinically in-apparent or very mild illness is
the commonest outcome of EV71 infection in this setting.
Seroprevalence of EV71 virus neutralizing antibodies in a
cross-sectional survey of infants, children and adults
To further explore the seroprevalence of EV71 virus neutralizing
antibodies, we performed virus neutralization assays in plasma
samples from an independent group of 275 infants aged 12 months
of age, 260 infants aged 18 months of age and 259 infants aged 24
months. We complemented this assessment in infants with plasma
samples from children 5–15 years of age. Consistent with the
previous results, the seroprevalence at 1 year of age was 8.3%, at 18
months of age it was 13.4% and by 2 yrs of age, 23.6%. Strikingly,
84% of children aged 5–15 yrs had detectable EV71 neutralizing
antibodies and there was a positive correlation between seroposi-
tivity and age (Fig. 3A). In contrast, the levels of EV71 Neut-Ab
declined over age groups (Kruskal-Wallis P,0.0001) (Fig. 3B)
Infusion of intravenous immunoglobulin (IVIG) in the
treatment of severe HFMD
Infusion of intravenous immunoglobulin (IVIG) has become the
standard of care for the treatment of severe HFMD in Southeast
Asia [12,13]. This treatment occurs despite the absence of any
evidence from randomized controlled trials to support its use. It is
plausible that IVIG preparations contain EV71-virus neutralizing
antibodies that could exert an anti-viral effect in vivo. To explore
this, we measured EV71-virus neutralizing antibody titres in IVIG
preparations routinely used for intravenous infusion in patients with
severe HFMD in Viet Nam. The two preparations, Humaglobin
(Synergy Diagnostics Pvt. Ltd., Hungary) and IVIG S (GreenCross,
Korean) both contained EV71-virus neutralizing antibody, with
‘‘Humaglobin’’ having slightly lower titres (median titre from 11
independent titrations was 438, 95% CI: 295–751)_than ‘‘IVIG S’’
(median titre from 3 independent titrations was 640, 95%CI: 640-
640). These data indicate that IVIG preparations being used in
clinical care and this setting have approximately equivalent levels of
EV71-virus neutralizing antibodies and this could be relevant to the
hypothesized efficacy of this treatment.
Discussion
This study describes the decay of maternally-derived EV71
neutralising antibodies and the age-specific seroincidence and
seroprevalence of EV71 in HCM City, Viet Nam between 2006
and 2009. These data contribute to our knowledge of EV71
prevalence in Southeast Asia, an important component in building
the case for vaccines and therapeutics against this emerging
pathogen. The incidence of EV71 infection calculated in our study
was even higher than that of dengue virus infection in infants
during the same period (5.6 vs 1.7 per 100 person-years) [11].
Maternally-derived neutralizing antibodies to EV71 were found
to be present in 55% of cord plasma samples and these antibodies
persisted for no longer than the first 6 months of life. These
findings are consistent with observations made in Taiwanese
infants [11,14,15] where the seroprevalence of Neut-Ab against
EV71 decreased from 35% at birth to 1% at 6 months of age. The
incidence of EV71 Neut-Ab seroconversion, which we assume to
be a sensitive marker of infection, was 5.6% and 14% in the first
and second year of life respectively. Strikingly, none of the infants
with seroconversions were ever clinically diagnosed with HFMD.
This suggests that the bulk of EV71 infections are clinically silent
or very mild. Infants spend the majority of their time in the home
and therefore this seems likely to be the location where EV71
infection is acquired, possibly from other members of the
household. However, analysis of the baseline characteristics of
the infants did not reveal any associations between seroconversion
and number of siblings, socioeconomic status of the household or
geographic location of residence.
That 80% of children (5–15 years) were seropositive suggests
that EV71 infection is highly prevalent in Vietnamese children.
Interestingly, Neut-Ab titres in children were significantly lower
than infants who had recently experienced infection. This likely
reflects the differences between an acute response post-infection in
the infants and homeostatic levels in older children that become
established months-to-years after infection. Whether these EV71
Neut-Ab titres persist for life is unknown, but since the
epidemiological profile of HFMD suggests older children and
adults are immune to clinical disease, it seems likely that Neut-Ab
or their corresponding memory B cells persist for decades after
infection occurs.
Somewhat surprisingly, the seroprevalence of EV71 Neut-Ab
was higher (80%) in children than in cord blood samples (55%).
Since cord blood reflects the mother’s immune status, this is likely
to be a reasonable estimate of the wider adult population. A 55%
EV71 seropositivity rate in Vietnamese cord blood samples is
consistent with that reported in previous studies from Germany
(42.8%), Singapore (44%) and Taiwan (50%) [1,3,14]. Amongst
the Vietnamese cord blood plasma samples that were positive, the
titre of EV71 Neut-Ab was lower than in infants with recent
infection. As observed above, this likely reflects the absence of
recent EV71 exposure in adults. A possible explanation for the
lower seroprevalence in adults relative to children (5–15 yrs) is true
lack of exposure. The circulation of EV71 in the south of Viet
Nam was first confirmed by viral culture in 2003 [2], thus it is
plausible that EV71 is a relatively new introduction to southern
Viet Nam. Additional seroprevalence studies and viral phyloge-
netics studies, as recently described for dengue in southern Viet
Nam [16], could help elucidate this.
Table 1. EV71 seroincidence in infants and young children, HCMC, Viet Nam.
Age (months)
EV71 seroconversion
N (%) No. of infants/children Person years
EV71 infection incidence rate per
100 person-years
0–12 17 (5.6%) 304 301 5.6
12–24 37 (12.2%) 303 261.5 14
doi:10.1371/journal.pone.0021116.t001
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caused by EV71, occurs in infants aged 0–24 months [2,8]. EV71
has been associated with more severe outcomes [2,4,17], but the
pathogenic basis for this remains unknown. Since enteroviruses
that cause HFMD are transmitted by fecal-oral routes, commu-
nity-based efforts to encourage hand hygiene, clean water supply
and sanitary conditions might be effective at limiting transmission
[18,19,20]. Vaccination against EV71 is an attractive option. Our
data, and those of others, indicates maternally derived Neut-Ab to
EV71 is lost by the time an infant is 6 months of age. Were a
vaccine available, the most pragmatic time to vaccinate would be
when infants are 9 months of age (co-inciding with measles
vaccination in many developing countries) or at 12 months of age.
There are some limitations to our study. First, the limit of
detection for the neutralization assay was 20. This was established
after preliminary experiments established that lower dilutions of
plasma resulted in a non-specific cytopathic effects on the cell
monolayer and secondly, because the volume of plasma available
was insufficient to run at much lower dilutions. This limit of
detection may have decreased the number of samples deemed
‘‘positive’’ in our study. Second, our cohorts of infants, children
and adults were primarily from HCMC- different results might be
observed in less urban and less developed areas of Viet Nam. We
also used a genotype B EV71 virus in our neutralization assays
even though the EV71 strains circulating in Viet Nam belong to
genotype C4 and C5 [2,9]. Although it is unknown if different
EV71 genotypes are uniformly neutralized by ‘‘standard’’
polyclonal immune sera, we believe this is likely given the
epidemiological evidence that recurrent episodes of EV71-
associated HFMD have never been documented in the same
individual.
This study provides the first report of the seroprevalence of
EV71 Neut-Abs in Vietnamese infants and children. It highlighted
the age-related prevalence of EV71 infection in the community of
Ho Chi Minh City. Although EV71 infections were addressed in
most of severe HFMD cases, our study documented that many
EV71 infections are clinically silent or very mild. Therefore,
further studies are needed to understand EV71 transmission and
its pathogenesis in severe disease so as to inform public health
interventions and clinical treatment approaches.
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